Chenyu Lin, Gautam Sajeev, Patrick J Stiff, Claudio G Brunstein, Corey Cutler, Guillermo Sanz, Caroline A Lindemans, Andrew R Rezvani, Rabi Hanna, Liang Piu Koh, Richard T Maziarz, William Y K Hwang, Yan Song, Qing Liu, Rocio Manghani, Smitha Sivaraman, James Signorovitch, Mitchell E Horwitz, Anthony D Sung
BACKGROUND: Omidubicel is an advanced cell therapy derived from umbilical cord blood (UCB) for use in allogeneic hematopoietic cell transplantation (HCT). A recent randomized phase 3 clinical trial demonstrated faster engraftment, shorter hospitalizations, and lower rates of infections with omidubicel when compared to standard UCB transplantation in patients with high-risk hematologic malignancies (Horwitz et al., Blood 2021). Despite the proven clinical benefits of omidubicel, its impact on health-related quality of life (HRQL) from the patient's perspective has not been described...
September 27, 2022: Transplantation and cellular therapy